| 严 海,黄 丹,胡清林,黄 昊,张 勇,史云天.奥沙利铂联合卡培他滨或替吉奥对晚期结肠癌患者血浆miR-21表达的影响[J].现代生物医学进展英文版,2017,17(17):3291-3294. |
| 奥沙利铂联合卡培他滨或替吉奥对晚期结肠癌患者血浆miR-21表达的影响 |
| Effects of Oxaliplatin Combined with Capecitabine/ Tegafur on Expressions of MiR-21 in Patients with Advanced Colon Cancer |
| Received:December 10, 2016 Revised:December 30, 2016 |
| DOI：10.13241/j.cnki.pmb.2017.17.022 |
| 中文关键词: 晚期结肠癌 奥沙利铂 卡培他滨 替吉奥 |
| 英文关键词: Advanced colon cancer Oxaliplatin Capecitabine Tegafur |
| 基金项目:四川省卫生厅科研课题(080278) |
|
| Hits: 356 |
| Download times: 174 |
| 中文摘要: |
| 摘要 目的：探讨奥沙利铂联合卡培他滨或替吉奥对晚期结肠癌患者血浆微小RNA-21（miR-21）表达水平的影响及疗效。方法：选择2013年6月至2016年6月我院接诊的90例晚期结肠癌患者，随机分为替吉奥组和卡培他滨组，每组45例。替吉奥组患者采用奥沙利铂联合替吉奥治疗，卡培他滨组患者采用奥沙利铂联合卡培他滨治疗。观察并比较两组患者治疗前后血清白介素-2（IL-2）、肿瘤坏死因子-α（TNF-α）、干扰素-γ（INF-γ）及miR-21水平变化、客观缓解率（ORR）以及不良反应。结果：治疗后，替吉奥组患者血清IL-2，TNF-α及INF-γ水平均高于卡培他滨组，而血浆miR-21水平低于卡培他滨组，差异具有统计学意义（P<0.05）；替吉奥组客观缓解率（ORR）高于卡培他滨组，而不良反应总发生率低于卡培他滨组，差异具有统计学意义（P<0.05）。结论：与卡培他滨相比，奥沙利铂联合替吉奥治疗晚期结肠癌的效果显著，可有效提高患者免疫力，抑制肿瘤发展，且不良反应较少，值得临床推广。 |
| 英文摘要: |
| ABSTRACT Objective: To study the effect of oxaliplatin combined with capecitabine and tegafur on the expressions of microRNA- 21(miR-21) in patients with advanced colon cancer and its curative efficacy. Methods: 90 patients with advanced colon cancer who were treated in our hospital from June 2013 to June 2016 were selected and randomly divided into the tegafur group and capecitabine group, with 45 cases in each group. The patients in the tegafur group were treated with oxaliplatin and tegafur, while the patients in the capecitabine group were treated with oxaliplatin and capecitabine. Then the serum levels of IL-2, TNF-α and INF-γ, and the expres- sions of miR-21, and the ORR and adverse reactions between the two groups were observed and compared before and after the treatment. Results: After the treatment, the serum levels of interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α) and interferon-γ (INF-γ) of pa- tients in the tegafur group were higher than those of the capecitabine group, while the expression of miR-21 was lower, and the differ- ences were statistically significant(P<0.05); The objective response rate(ORR) in the tegafur group was higher than that of the capecitabine group, while the incidence of adverse reactions was lower, and the differences were statistically significant (P<0.05). Conclusion: Compared with capecitabine, oxaliplatin and tegafur has better clinical efficacy on the treatment of advanced colon cancer, which can improve the immune functions of patients and inhibit the expansions of tumor, with less adverse reactions, and it is worthy of clinical application. |
|
View Full Text
View/Add Comment Download reader |
| Close |
